Literature DB >> 20812333

Physician assessment of ulcerative colitis activity correlates poorly with endoscopic disease activity.

Miguel Regueiro1, Joseph Rodemann, Kevin E Kip, Melissa Saul, Jason Swoger, Leonard Baidoo, Marc Schwartz, Arthur Barrie, David Binion.   

Abstract

BACKGROUND: Subjective physician assessment is the cornerstone of routine ulcerative colitis (UC) management. Endoscopic and histologic assessment of UC provides objective measures of inflammatory disease activity. The level of agreement between physician impression of UC activity and endoscopic disease activity has not been evaluated. The aim was to assess the level of agreement between physician's clinical impression of UC disease activity and endoscopic and histologic findings of inflammation.
METHODS: Using the Medical Archival Retrieval System at the University of Pittsburgh Medical Center, we reviewed clinical information on all UC patients between 1995 and 2008 who had clinic visits recorded prior to colonoscopy. Clinical UC disease activity was defined by the physician's clinical impression and the endoscopic and histologic activity by colonoscopy with biopsy. The level of agreement between colonoscopy assessment of UC with histologic and clinical assessment was determined by sensitivity, specificity, positive and negative predictive values, and the kappa coefficient.
RESULTS: There were 369 UC patients who had a clinic visit proximate to a colonoscopy. The mean age of patients was 46 ± 16 years (50% female). The performance of clinical impression in recognizing disease activity, as determined by endoscopy, was relatively poor: sensitivity = 56.0%, predictive value negative = 56.8%, kappa coefficient = 0.35. In contrast, the performance of histological evaluation in recognizing disease activity was markedly better: sensitivity = 93.5%, predictive value negative = 89.1%, kappa coefficient = 0.70.
CONCLUSIONS: The physician's clinical impression of UC activity shows poor agreement with endoscopy and histology, with over one-third of patients with chronic inflammation underrecognized by clinical impression. The consequences of underestimated UC activity by clinical assessment may include undertreatment of active disease and uncontrolled chronic inflammation.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20812333     DOI: 10.1002/ibd.21445

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  11 in total

Review 1.  Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

Authors:  Robert Battat; Parambir S Dulai; Christopher Ma; Vipul Jairath; Brian G Feagan; William J Sandborn; Reena Khanna
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-04

2.  Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis.

Authors:  Burton I Korelitz; Keith Sultan; Megha Kothari; Leo Arapos; Judy Schneider; Georgia Panagopoulos
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

3.  Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

4.  The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.

Authors:  Aaron Yarlas; Mary Kaye Willian; Arpita Nag
Journal:  Qual Life Res       Date:  2021-03-02       Impact factor: 4.147

5.  The valuable role of endoscopy in inflammatory bowel disease.

Authors:  Matthew J Hamilton
Journal:  Diagn Ther Endosc       Date:  2012-02-29

6.  Indian Society of Gastroenterology consensus on ulcerative colitis.

Authors:  Balakrishnan S Ramakrishna; Govind K Makharia; Philip Abraham; Uday C Ghoshal; Venkataraman Jayanthi; Brij Kishore Agarwal; Vineet Ahuja; Deepak K Bhasin; Shobna J Bhatia; Gourdas Choudhuri; Sunil Dadhich; Devendra C Desai; Gopal Krishna Dhali; Bhaba Dev Goswami; Sanjeev K Issar; Ajay K Jain; Rakesh Kochhar; Ajay Kumar; Goundappa Loganathan; Sri Prakash Misra; C Ganesh Pai; Sujoy Pal; Anna Pulimood; Amarender S Puri; Ganesh N Ramesh; Gautam Ray; Shivaram P Singh; Ajit Sood; Manu Tandan
Journal:  Indian J Gastroenterol       Date:  2012-10-25

7.  Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms.

Authors:  Chaolan Lv; Xinmei Zhao; Hongxiang Gu; Liyun Huang; Sanxi Zhou; Fachao Zhi
Journal:  Med Sci Monit       Date:  2016-12-07

8.  Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.

Authors:  Aaron Yarlas; Geert D'Haens; Mary Kaye Willian; Megan Teynor
Journal:  Inflamm Bowel Dis       Date:  2018-01-18       Impact factor: 5.325

9.  Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study.

Authors:  Triana Lobatón; Talat Bessissow; Alexandra Ruiz-Cerulla; Gert De Hertogh; Raf Bisschops; Jordi Guardiola; Gert Van Assche; Severine Vermeire; Marc Ferrante
Journal:  United European Gastroenterol J       Date:  2018-01-08       Impact factor: 4.623

10.  Correlation of endoscopic disease severity with pediatric ulcerative colitis activity index score in children and young adults with ulcerative colitis.

Authors:  Basavaraj Kerur; Heather J Litman; Julia Bender Stern; Sarah Weber; Jenifer R Lightdale; Paul A Rufo; Athos Bousvaros
Journal:  World J Gastroenterol       Date:  2017-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.